Restricted accessResearch articleFirst published online 2012-10
Onset of Abnormal Movements and Cardiovascular Symptoms after Acute Change in Complex Polypharmacy in a Child with Attention-Deficit/Hyperactivity Disorder and Mood Symptoms
BiedermanJ, KrishnanS, ZhangY, McGoughJJ, FindlingRL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther, 29:450–463. 2007.
2.
BlaisdellGD. Akathisia: A comprehensive review and treatment summary. Pharmacopsychiatry, 27:139–146. 1994.
3.
HollisCP. Acute dyskinesia on starting methylphenidate after risperidone withdrawal. Pediatr Neurol, 37:287–288. 2007.
4.
LipkinPH, GoldsteinIJ, AdesmanAR. Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. Arch Pediatr Adolesc Med, 148:859–861. 1994.
5.
McLarenJL, CaubleS, BarnettRJ. Aripiprazole induced acute dystonia after discontinuation of a stimulant medication. J Clin Psychopharmacol, 30:77–78. 2010.
6.
PliszkaS. AACAP Work Group on Quality Issues: Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 46:894–921. 2007.
7.
RodnitzkyRL. Drug-induced movement disorders in children. Semin Pediatr Neurol, 10:80–87. 2003.
8.
SabuncuogluO. Risperidone-to-methylphenidate switch reaction in children: Three cases. J Psychopharmacol;, 21:216–219. 2007.
9.
SachdevP. The epidemiology of drug-induced akathisia: Part I. Acute akathisia. Schizophr Bull, 21:431–449. 1995.
10.
ScahillL, ChappellPB, KimYS, SchultzRT, KatsovichL, ShepherdE, ArnstenAF, CohenDJ, LeckmanJ. A placebo-controlled study of guanfacine in the treatment of children with tic disorders, attention deficit hyperactivity disorder. Am J Psychiatry, 158:1067–1074. 2001.
11.
SeneckyY, LobelD, DiamondGW, WeitzR, InbarD. Isolated orofacial dyskinesia: A methylphenidate-induced movement disorder. Pediatr. Neurol, 27:224–226. 2002.
12.
SpencerTJ, BiedermanJ, FaroneS, MickE, CoffeyB, GellerD, KaganJ, BearmanSK, WilensT. Impact of tic disorders on ADHD outcome across the lifecycle: Findings from a group of adults with and without ADHD. Am J Psychiatry, 158:611–617. 2001.
13.
SpillerHA, GriffithJRK, AndersonDL, WeberJA, AleguasA. Poison centers detect an unexpectedly frequent number of adverse drug reactions to lisdexamfetamine. Ann Pharmacother, 42:1142–1143. 2008.
WalkupJ. Work Group on Quality Issues: Practice parameter on the use of psychotropic medication in children and adolescents. J Am Acad Child Adolesc Psychiatry, 48:961–973. 2009.
16.
WaynePA.Vyvanse™ (lisdexamfetamine dimesylate) [product information]Shire US Inc., February2007.
17.
WilensT, SpencerT, BiedermanJ, WozniakJ, ConnorD. Combined pharmacotherapy: An emerging trend in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry, 14:110–112. 1995.
